The potent growth-inhibitory activity of cytokines of the transforming growth factor-b (TGF-b) superfamily and their widespread expression in epithelia suggest that they may play an important role in the maintenance of epithelial homeostasis. To analyse TGF-b mediated tumor suppressor activity in the liver, we generated transgenic mice overexpressing a dominant negative type II TGF-b receptor in hepatocytes under control of the regulatory elements of the human C-reactive protein gene promoter. Transgenic animals exhibited constitutive and liverspeci®c transgene expression. The functional inactivation of the TGF-b signaling pathway in transgenic hepatocytes was shown by reduced TGF-b induced inhibition of DNA synthesis in primary hepatocyte cultures. Liver morphology and spontaneous tumorigenesis were unchanged in transgenic mice suggesting that interruption of the signaling of all three isoforms of TGF-b in hepatocytes does not disturb tissue homeostasis in the liver under physiological conditions. However, following initiation with the carcinogen diethylnitrosamine and tumor-promotion with phenobarbital transgenic mice exhibited a moderate albeit signi®cant increase in the incidence, size and multiplicity of both preneoplastic tissue lesions in the liver and of hepatocellular carcinomas. These results give in vivo evidence for a tumor suppressor activity of the endogeneous TGF-b system in the liver during chemical hepatocarcinogenesis. Oncogene (2001) 20, 5015 ± 5024.
Introduction
The transforming growth factor-b (TGF-b) superfamily includes a large number of structurally related polypeptide growth factors, which include the TGF-b family, the activin/inhibin family, the bone morphogenetic proteins (BMPs) and the growth and dierentiation factors (GDFs); (Piek et al., 1999) . TGF-b is expressed in complex temporal and tissue-speci®c patterns and exerts a variety of signaling functions regulating cell growth, dierentiation, migration and cell death (Piek et al., 1999) . TGF-b conveys signals via two serine/threonine kinase receptors, type I and type II, forming a ternary complex with the ligand TGF-b (Massague et al., 2000) . In this complex the serine/ threonine kinase domain of the type II receptor phosphorylates serine residues in a serine-and glycine-rich region adjacent to the aminoterminal boundary of the kinase domain (GS domain) of the type I receptor. This phosphorylation step activates the kinase domain of the type I receptor which in turn phosphorylates one of several pathway-speci®c Smad proteins (Massague et al., 2000) .
While alterations leading to a gain of TGF-b activity are thought to play a central role in ®brotic disorders characterized by excessive accumulation of interstitial matrix (Branton and Kopp, 1999; Kanzler et al., 1999) , the disruption of TGF-b signaling by somatic mutations of its receptors might predispose to, or even cause cancer (Kelly and Rizzino, 1999) . TGF-b has strong antiproliferative activity on epithelial and hematopoietic cells, cell types from which the majority of human malignancies are derived (Alexandrow and Moses, 1995; Massague et al., 2000) . However, tumor-derived cell lines have frequently lost this antiproliferative response. Resistance to the TGF-b mediated growth inhibition seems to be a late event in tumor progression (Haddow et al., 1991) , and it has been shown for a variety of human tumors or tumor cell lines that reduced antiproliferative response to TGF-b is due to mutations of the type II TGF-b receptor Shin et al., 2000; Park et al., 1994; , Garrigue-Antar et al., 1995 Knaus et al., 1996; Kimchi et al., 1988; Kalkhoven et al., 1995) . More recently, disruption of the TGF-b pathway in cancer has also been demonstrated at the level of the Smad signal transducers (Eppert et al., 1996; Hahn et al., 1996) .
Mutations of the type II TGF-b receptor in cancers with microsatellite instability have been ascribed to a defective DNA mismatch repair system (Dietmaier et al., 1997) . In accordance with these ®ndings, Lowsky and coworkers could recently show that lymphomas of MSH2 knockout mice (MSH27/7) ± mice lacking the mismatch repair system ± frequently exhibit mutations in the type II TGF-b receptor (Lowsky et al., 2000) . Apart from mutations of the type II TGF-b receptor, downregulation or lack of expression of this receptor might be another means of escape from TGF-b mediated growth control as shown for prostate cancer (Cardillo et al., 2000) , breast cancer (Gobbi et al., 2000) and also for hepatocellular carcinoma (Bedossa et al., 1995; Kiss et al., 1997; Factor et al., 1998) . Some manifest hepatocellular carcinomas showed a marked reduction or loss of expression of TbRII (Bedossa et al., 1995; Kiss et al., 1997; Factor et al., 1998) . Since this ®nding was not con®rmed by others (GraslKraupp et al., 1998; Abou-Shady et al., 1999 ) the role of TGF-b signaling in hepatocarcinogenesis remains elusive. In addition, many cancers are associated with increased local and systemic levels of TGF-b (Gold, 1999) . Thus, on one hand TGF-b may stimulate malignant progression itself, possibly by modulating cell-matrix interactions, by its immunosuppressive activity or by enhancing angiogenesis (Arrick et al., 1992 , Factor et al., 1998 . On the other hand, TGF-b can have tumor suppressor activity, most likely due to its growth inhibitory eects. Additionally, TGF-b induced apoptosis of preneoplastic cells might contribute to anti-tumor defense.
To elucidate the complex role of TGF-b signaling during hepatocarcinogenesis we subjected transgenic mice overexpressing a dominant negative mutant of the type II TGF-b receptor (DkTbRII) in hepatocytes under the control of the human C-reactive protein (CRP) gene promoter to a hepatocarcinogenesis protocol (Pitot et al., 1987 . We studied for altered susceptibility to spontaneous and chemically induced carcinogenesis. Our results clearly indicate that the TGF-b system has tumor suppressor activity in chemically induced liver carcinogenesis even though it does not appear to be such a crucial regulator in hepatocarcinogenesis in comparison to e.g. colon and squamous cell carcinoma formation.
Results

Generation of CRP/DkTbRII transgenic mice
To disrupt the signal-transduction pathway for TGF-b in the liver we used a dominant negative mutant of the type II receptor for TGF-b lacking the intracellular kinase domain (DkTbRII; Brand et al., 1993) . For liver speci®c expression of DkTbRII we chose the promoter of the human CRP-gene (Figure 1 ) ± an acute phase protein gene ± in a version with a high level constitutive expression (Murphy et al., 1995) . Five founder animals were generated. Three of them were fertile and gave rise to three transgenic lines TgN(CdkTbRII) 6 Mbl, TgN(CdkTbRII) 10 Mbl and TgN(CdkTbRII) 11 Mbl, further refered to as line 6, line 10, line 11, respectively. Mice of line 10 and line 11 were further analysed and submitted to the DEN/PB hepatocarcinogenesis protocol.
Analysis of transgene expression
To demonstrate transgene derived DkTbRII expression in transgenic mice, RT ± PCR analysis was performed using primers derived from the 5'-untranslated region of the CRP-gene and the human DkTbRII. A diagnostic band at 605 bp was observed in the analysis of both male and female transgenic mice of lines 10 and 11 when RNA extracted from livers was used as templates. As a control reaction construct DNA was used as a template resulting in a band at 883 bp due to the presence of intron-sequences in the construct (Figure 2a ). Northern blot hybridization of total RNA extracted from livers showed a stronger transgene expression in male mice of both lines 10 and 11 (data not shown). This is in accordance with the observation of Ruether et al. (1993) who showed a higher transgene expression in male CRP-transgenic mice. Northern blot analysis with total RNA extracted from multiple organs showed a strict liver speci®c expression of DkTbRII (Figure 2b ). The cDNA of DkTbRII, detecting endogeneous and transgene derived TbRII, was used as hybridization probe. Western blot analysis of protein extracts from liver homogenates from mice of line 11 and non-transgenic mice using an antibody against the human type II TGF-b receptor detected a 44 kDa band only in the extracts from transgenic mice representing the DkTbRII (Figure 2c ). Immunhistochemical staining of liver cryosections with an antibody speci®c for the human type II TGF-b receptor (recognizing the extracellular part of the type II TGF-b receptor) showed expression of DkTbRII at the hepatocellular plasma membrane of transgenic mice. The expression pattern of DkTbRII in transgenic mice in comparison to wild type mice could be best visualized following induction of the CRP-promoter by intraperitoneal injection of LPS (Figure 3a,b) . In order to con®rm the inactivating capacity of the dominant negative type II TGF-b receptor, the ability of transgenic and non-transgenic primary hepatocytes to escape the inhibitory eect of TGF-b on DNA synthesis was examined. We isolated hepatocytes from transgenic mice (male, line 11) and non-transgenic littermates (four independent experiments). DNA synthesis was measured by [ 3 H]thymidine incorporation after preincubation with various concentrations of TGF-b 1 (Figure 4 ). Wild type hepatocytes showed a strong and dose dependent responsiveness to TGF-b 1 . TGF-û 1 at a concentration of 0.25 ng/ml led to over 50% inhibition of DNA synthesis, at 2.5 ng/ml TGFb 1 to over 80% inhibition. In contrast, hepatocytes from transgenic mice exhibited a markedly reduced inhibition of [ 3 H]thymidine incorporation at a concentration of 0.25 ng/ml (P50.05). At a concentration of 2.5 ng/ml TGF-b 1 only a 40% inhibition. These results demonstrate that the dominant negative type II TGF-b receptor interferes with the signal transduction pathway for TGF-b in primary hepatocytes. Since the success of the dominant negative approach relies on the level of expression of the transgene we compared the expression of the dominant negative receptor in the in vitro system and the in vivo situation. Therefore, the level of mRNA expression of the dominant negative receptor of freshly isolated transgenic hepatocytes and transgenic hepatocytes after 72 h of culture was compared to the DkTbRII mRNA expression of uninduced transgenic mice and transgenic mice 64 weeks after DEN/PB treatment. Transgene expression decreased signi®cantly after 72 h of culture ( Figure 5 ). In fact, transgene expression in 3 days old hepatocyte cultures was below the levels seen in uninduced transgenic mice, freshly isolated hepatocytes and Figure 2 (a) RT ± PCR analysis was used to assess transgene derived DkTbRII mRNA expression in the liver of transgenic animals. The primer pair to detect transgene derived DkTbRII was derived from the 5'-untranslated region of the human CRPgene and the reverse primer from human TbRII. This primer pair produces a 605 bp diagnostic band. Lane 1 corresponds to negative control. RNA extracted from livers of line 11 (male; lane 3 and female; lane 4) as well as line 10 (male; lane 5 and female; lane 6) were used as templates. The positive control (lane 2) consisted of the construct DNA and included an intron giving rise to a band at 883 bp. (b) Northern blot analysis with total RNA extracted from dierent organs of transgenic mice (male, line 11) showed liver speci®c expression of the transgene (1). There was no detectable DkTbRII expression in intestine (2), muscle (3), spleen (4), kidney (5), brain (6) and heart (7). (c) Western blot analysis for TbRII protein in liver homogenates from transgenic (line 11) and wild type mice using polyclonal antibody (L-21) speci®c for the type II TGF-b receptor. Lane 1: transgenic line 11, male; lane 2: wild type mice, male Induction of hepatocellular carcinoma in transgenic and wild-type mice Heterozygous animals of both lines showed no obvious abnormalities at autopsy. Liver, spleen, kidneys, intestine, lung and heart did not exhibit any histopathological abnormality. Although not precisely measured or subjected to statistical analysis there was no apparent shortage in the life span of transgenic mice compared to wild type mice. To determine whether hepatocellular loss of TGF-b responsiveness might aect susceptibility of the mice to spontaneous carcinogenesis in the liver we sacri®ed 60 transgenic mice at the age of 18 ± 24 months. We performed a complete autopsy and examined the liver, lung, kidneys, intestine, spleen and heart for macroscopically visible tumors. None of the untreated DkTbRII transgenic mice showed evidence for hepatocellular carcinoma nor for any other malignancy (data not shown). In order to investigate the in¯uence of TGF-b signaling during chemical hepatocarcinogenesis we subjected transgenic mice (lines 10 and 11) as well as non-transgenic littermates to a DEN-initiated/PBpromoted hepatocarcinogenesis protocol. Animals, eight in each group, were sacri®ced starting at week 8 after onset of the PB-promotion and thereafter in 8 week-intervals up to week 64. Since transgenic animals suered progressively from cachexia and tumor burden we decided to terminate the study at week 64. At that time point all remaining animals were sacri®ced. Mice were subjected to complete necropsy and livers were preserved for histopathology.
Preneoplastic hepatic lesions (basophilic, eosinophilic, tigroid cell, clear cell and mixed foci) were ®rst detected at week 40 in both transgenic lines. In wild type mice the ®rst preneoplastic lesion was found at week 48. The incidence of preneoplastic lesions increased progressively with time, respectively the duration of PB-treatment. Remarkably, the incidence of preneoplastic lesions was signi®cantly higher in both transgenic lines at weeks 56 and 64 (P50.05) in comparison to wild type animals ( Figure 6 ). At week 64 only 9% (four of 45) of non-transgenic, but 38% (21 of 55, line 10; P50.005) and 33% (19 of 58, line 11; P50.005) of the DkTbRII transgenic mice had preneoplastic lesions on liver histology. Additionally, 38% of the transgenic animals had multi-focal preneoplastic lesions in the liver whereas all lesions in wild type mice were singular. Hepatocellular carcinomas were ®rst observed 8 weeks after the appearance of preneoplastic lesions. Figure 7 shows the cumulative incidence of HCC from week 48. 5.5% (two of 37) of the non-transgenic, but 28.5% (13 of 46, line 10; P50.05) and 20% (10 of 50, line 11; P50.05) of the transgenic mice had histologically proven HCCs. Thirty-®ve per cent of the aected transgenic animals of both lines, but no wild type animal had more than one hepatocellular carcinoma. There was no dierence in the relation of liver-to bodyweight in wild type compared to transgenic animals (data not shown). However, there were more mice with macroscopic tumors (40.2 cm diameter) in the transgenic group in comparison to the wild-type group. From week 48 on 13% (®ve of 37) of wild type animals, but 26% (12 of 46, line 10) and 22% (13 of 58, line 11) of DkTbRII transgenic mice had macroscopically visible tumors in the liver. There was no signi®cant dierence in the frequency of hepatocellular carcinoma between male and female mice and there was no evidence of any metastasis of hepatocellular carcinoma in lung, lymph nodes, kidney, intestine, heart and spleen (data not shown).
Discussion
In the present work, it is demonstrated that interruption of the TGF-b signaling pathway in hepatocytes does not disturb tissue homeostasis under physiological conditions, but increases the susceptibility to chemical induced hepatocarcinogenesis. This suggests that the TGF-b signaling pathway has a tumor suppressor activity in the liver in vivo.
The relationship between TGF-b and cancer is complex (Gold, 1999) . The paradigm that is emerging from the experimental evidence accumulated over the past decade is that TGF-b can play two dierent and opposite roles with respect to the process of malignant progression: TGF-b may act both as a potent tumor suppressor as well as a tumor promoter. Recent work has shown that resistance to TGF-b is the consequence of loss or mutational inactivation of types I and II TGF-b receptors, as well as down-stream signaling components, which has been shown for a variety of human tumors and tumor cell lines Park et al., 1994; Garrigue-Antar et al., 1995; Eppert et al., 1996; Kim et al., 1996) . It seems that loss or diminished expression of type I TGF-b receptor is an event much rarer than loss of TbRII, but it has also been reported to correlate with the malignant phenotype in some rodent or human cancer cells . Reintroduction of the receptor in cells derived from TbRII-negative cancers restores sensitivity to TGF-b and reduces their tumorigenicity (Inagaki et al., 1993; Chang et al., 1997) . These ®ndings have led to the proposal of tumor suppressor activity of the TGF-b signaling pathway (Markowitz and Roberts, 1996) . Experimental data from transgenic mice overexpressing a dominant negative mutant of the type II TGF-b receptor in lung and in mammary glands as well as in skin have con®rmed this concept showing promotion of chemical carcinogenesis in organs with disruption of the TGF-b signaling pathway (Amendt et al., 1998; BoÈ ttinger et al., 1997a,b) . With respect to hepatocarcinogenesis it has been shown that there is reduced TbRII expression in liver cirrhosis, which might be considered as a preneoplastic condition, as well as in manifest human HCC (Kiss et al., 1997; Bedossa et al., 1995; Kiso et al., 1994) . Hepatocytes from cirrhotic livers exhibited a 50% reduction of TbRII expression in comparison to normal hepatocytes. Accordingly, twofold higher concentrations of TGF-b were necessary to induce a 50% inhibition of DNA synthesis in these hepatocytes (Kiso et al., 1994) . Further evidence comes from DEN-initiated HCC in mice in which a reduction of TbRII has also been reported (Lim et al., 1999) . However, it seems that downregulation of the TbRII receptor rather than mutation or deletion of the TbRII occurs more frequently in human hepatocarcinogenesis (Kiss et al., 1997; Bedossa et al., 1995; Kiso et al., 1994; Saeki et al., 2000; Salvucci et al., 1999) .
If the TGF-b signaling pathway has strong tumor suppressor activity in the liver, one would expect that inhibition of TGF-b signaling would lead to an increased susceptibility to spontaneous or induced tumorigenesis. However, we did not ®nd spontaneous hepatocellular carcinomas in DkTbRII transgenic animals during an observation period of 418 months. Similar data have previously been generated in other organ systems showing no increased frequency of spontaneous cancer in transgenic mice with tissue- Figure 6 Cumulative frequency of preneoplastic hepatic lesions calculated from week 40, the ®rst time point of detection of preneoplastic lesions in transgenic mice (lines 10 and 11). The frequency of preneoplastic hepatic lesions increased progressively and reached statistical signi®cance when compared to nontransgenic mice at weeks 56 and 64 in both transgenic lines (P50.05) Figure 7 Cumulative frequency of hepatocellular carcinoma calculated from week 48, the ®rst time point of detection of hepatocellular carcinoma in transgenic line 10. The cumulative frequency of hepatocellular carcinomas increased progressively to 28.5% of animals (line 10) and 20% (line 11) at week 64, which was signi®cantly dierent in comparison to non-transgenic mice (P50.05) Oncogene TGF-b in chemical hepatocarcinogenesis S Kanzler et al speci®c overexpression of DkTbRII in the skin (Amendt et al., 1998; Wang et al., 1997) , mammary glands, lung (BoÈ ttinger et al., 1997a) or in the pancreas (BoÈ ttinger et al., 1997b) . This indicates that loss of TGF-b responsiveness is not an initiating or strongly predisposing, but rather a late event during carcinogenesis. One potential reason may be the functional redundancy with respect to the growth inhibitory mechanisms of TGF-b in the liver. Under physiological circumstances other TGF-b related or unrelated cytokines may be involved. For example activin, a member of the TGF-b superfamily which acts via dierent receptors, is a potent inhibitor of hepatocellular growth (Russell et al., 1999) and may be responsible for tissue homeostasis in the liver in case of disruption of TGF-b signaling pathway.
Our study shows that loss of TGF-b responsiveness cooperates with the initiating events induced by carcinogen treatment and further propagation by tumor promoters, ®nally leading to a more rapid development and higher frequency of preneoplastic lesions in the liver as well as of hepatocellular carcinomas. However, disruption of the TGF-b signaling pathway seems to be of minor importance in hepatocarcinogenesis in comparison to other epithelial carcinomas: Overexpression of DkTbRII in the lung, pancreas, mammary gland or skin led to much higher discrepancy in onset and incidence of tumor development between tissues of transgenic mice and wild type mice (BoÈ ttinger et al., 1997a,b; Amendt et al., 1998) . This is in accordance with histopathological ®ndings giving a very heterogenous picture with respect to the presence or absence of functional TGF-b type II receptors in HCCs (Kiss et al., 1997; Bedossa et al., 1995; Factor et al., 1998; Grasl-Kraupp et al., 1998; Abou-Shady et al., 1999) . In addition, a potential reason for this dierence may be once more that TGFb related or unrelated cytokines compensate for decreased biological eects of TGF-b in the liver during chemical hepatocarcinogenesis.
What are the eector mechanisms of increased tumorigenesis in DkTbRII transgenic mice? Increased cell proliferation and/or reduced apoptosis of initiated hepatocytes are potential mechanisms responsible for increased tumorigenesis. There is now a large body of evidence that TGF-b can induce hepatocellular apoptosis in vitro and in vivo (Sanderson et al., 1995; Oberhammer et al., 1992) . However, the exact mechanism by which TGF-b mediates apoptosis is not completely understood. Induction of proapoptotic genes such as p53 and bax as well as the activation of caspase-8 have been shown for liver epithelial cells (Teramoto et al., 1998; Shima et al., 1999) . Additionally, another family of TGF-b induced transcription factors, known as TIEG 1 and TIEG 2, has been shown to mediate apoptosis (Ribeiro et al., 1999; Cook et al., 1998) . A de®ciency of apoptosis of initiated cells would ®nally result in a greater pool of cells that are a target for additional mutations required for malignant conversion.
Control of cell proliferation by maintaining cells in the G 0 phase of the cell cycle is a further function of TGF-b (Wu et al., 1993) . In epithelial cells, including hepatocytes, TGF-b-induced inhibition of cell cycle progression is due to transcriptional downregulation of genes required for proliferation (Alexandrow and Moses, 1995; Sugiyama et al., 1997) and to inhibition of cyclin-dependent kinase (CDK) activities by induction/regulation of the CDK inhibitors p15, p21, and p27 (Sugiyama et al., 1997; Hannon and Beach, 1994; Polyak et al., 1994) . These mechanisms contribute to maintain the retinoblastoma protein (pRb) in a hypophosphorylated state, a process critical for the growth suppressive function of TGF-b (Laiho et al., 1990) . Cells with reduced TGF-b responsiveness may therefore be able to exit quiescence more readily and may further increase the pool of proliferating cells augmenting the risk of cancer induction. Furthermore, the maintenance of genomic stability by TGF-b might be an additional mechanism to explain the increased tumorigenesis in CRP/DkTbRII transgenic mice ± particularly in the later stages (Glick et al., 1997) .
An additional factor promoting hepatocarcinogenesis seems to be increased local levels of TGF-b in hepatocellular carcinomas (Ito et al., 1991) . In this context, it was shown that constitutive expression of active TGF-b 1 transgene in mouse liver predisposed to both spontaneous and chemically induced hepatocellular carcinoma (Factor et al., 1997) . Furthermore, coexpression of c-myc and mature TGF-b 1 in the liver further accelerates hepatocarcinogenesis that is associated with reduced TbRII expression (Factor et al., 1998) . The concept of decreased TbRII expression during hepatocarcinogenesis is also con®rmed in the cmyc/TGF-a transgenic mouse model which exhibit a high frequency of TbRII-negative preneoplastic foci and TbRII-negative HCC (Santoni-Rugiu et al., 1999) .
In conclusion, we have shown that disruption of the TGF-b signaling by overexpression of DkTbRII in hepatocytes does not lead to spontaneous changes in liver morphology, particularly not in an increase of spontaneous HCC. In contrast, during chemically induced hepatocarcinogenesis a higher frequency and multiplicity of preneoplastic and neoplastic lesions in the liver can be observed. This means that disruption of the TGF-b signaling pathway plays a role during the promotion/progression phase of hepatocarcinogenesis. The presented animal model will allow to further elucidate eector mechanisms by which disruption of TGF-b signaling leads to increased tumorigenesis in the liver. A focus of further investigation will be to study a potential de®ciency of TGF-b induced apoptosis in preneoplastic hepatocytes of DkTbRII transgenic mice, since this might be the key event leading to malignant conversion.
Materials and methods
Construction of the DkTbRII expression vector and generation of transgenic mice
For transgene expression the human CRP-gene was chosen. Of several truncated versions of this gene construct 4 (Murphy et al., 1995) was kindly provided by U Ruether (Hannover, Germany). This version consisted of 1.7 kb 5' of the cap site and 1.6 kb 3' of the poly(A) + site, corresponding to the BamHI ± BamHI fragment at 71.7 kb to +3.91 kb as described in detail elsewhere (Murphy et al., 1995) . This version of the CRP-gene is characterized by a comparatively high level of constitutive expression and an additional potential for induction upon acute phase reaction (Murphy et al., 1995) . Out of construct 4 we excised an EcoRI fragment (position 230 to 2017) containing the coding region of exon 1 and exon 2, the intron and a part of the 3'-untranslated region (3'-UTR). An oligonucleotide with three single cut restriction sites (AscI, PmeI and SmaI and EcoRI compatible ends was ligated in the EcoRI site (5'-TTG GCG CGC CGT TTA AAC CCG GG-3'). The 5'-EcoRI site was destroyed by this insertion. Subsequently, the intron of the hCRP gene was ampli®ed by PCR. The sequence of the 5'-primer was 5'-TGC TTT TGG CGC GCC AGG TAA G-3' (position 312 to 334) and included an AscI restriction site. The sequence of the 3'-primer was 5'-AGC CTT CCC GGG TAT GTC TGT G-3' (position 624 to 603) and included a SmaI restriction site (Whitehead et al., 1983) . The 310-base pair PCR product was inserted into the AscI ± SmaI restriction sites of the construct. Finally, the blunt-ended cDNA of the human type TGF-b II receptor lacking the cytoplasmatic kinase domaine (DkTbRII) was inserted into the SmaI-site of the expression cassette (Brand et al., 1993) (Figure 1 ). Transgenic mice were generated according to standard procedures (Hogan et al., 1986 ) by microinjection of a 7.5 kb S®I vector-free DNA fragment (Figure 1 ) into fertilized eggs of FVB/NHSD mice. Ospring tail DNA was isolated 3 weeks after birth and analysed for the presence of the transgene by Southern hybridization using a 1.3 kb EcoRI-fragment of the human CRP-gene (Figure 1) or by PCR. The 5'-primer was derived from the human CRP-intron from position 330 to 351 (5'-TAA GGG CCA CCC CAG GCT ATG-3') (Whitehead et al., 1983) and the 3'-primer was derived from the human TbRII from position 416 to 437 (5'-AGC CGC AGC TTG GAC AGG ATC-3') (Lin et al., 1992) .
Northern blot analysis
Total RNA was isolated from various mouse organs by extraction in guanidinium thiocyanate as described previously (Chomczynski and Sacchi, 1987) . Aliquots (15 mg) of total RNA were separated on 1% agarose gels containing 2.2 M formaldehyde and blotted onto nylon membranes (Hybond N, Amersham, Braunschweig, Germany). Prior to electrophoresis ethidium bromide was added to the RNA samples to enhance staining in order to assess the loading and the transfer eciency of each RNA sample. Filters were hybridized with the 32 P-labeled human DkTbRII cDNA (Figure 2b ) or a 1.3 kb EcoRI fragment from the hCRPgene ( Figure 5 ) and processed at high stringency as described (Church and Gilbert, 1984) .
RT ± PCR analysis
RT ± PCR analysis was performed using total RNA from the liver. Reverse transcription was accomplished using an RT ± PCR kit according to the manufacturer's instructions (Stratagene, LaJolla, CA, USA). PCR was performed using vent (exo-) DNA-polymerase (New England Biolabs, Schwalbach, Germany) in 35 cycles. Primer pairs were purchased from MWG-Biotech (Ebersberg, Germany). Primer pairs for both endogenous BMP-6 speci®c RNA and transgene derived RNA were spanning introns. The primer pair to detect transgene derived DkTbRII was derived from the 5'-untranslated region the human CRP-gene from position 166 ± 187 (5'-TAG CCC CTG AAC TTT CAG CCG-3') (Ciliberto et al., 1987) and the reverse primer from the human TbRII from position 423 ± 444 (5'-TGC ACT CAT CAG AGC TAC AGG-3') (Lin et al., 1992) . This primer pair generated a 605 bp diagnostic fragment with templates derived from appropriate transgenic tissues. To control the reverse transcription a primer pair speci®c for the murine BMP-6 was used consisting of a forward primer from position 536 ± 556 (5'-CCT TGA ACC GCA AGA GTC TCC-3') and a reverse primer from position 751 ± 771 (5'-CCT GTA GAC GCG GAA CTC AGC-3') as deduced from the sequence of the murine gene for BMP-6 (Gitelman et al., 1997) . This primer pair generated a 235 bp diagnostic fragment.
Detection of DkTbRII protein expression in the liver by Western blot hybridization
For Western blot analysis liver proteins of transgenic and non-transgenic mice were separated by electrophoresis in a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel, transferred to nitrocellulose membranes (Millipore, Eschborn, Germany) and blocked in 5% nonfat milk powder and 0.1% Tween 20 in buered saline (PBS-T). For detection 1 mg/ml of a polyclonal antibody speci®c for the type II TGF-b receptor (L-21, Santa Cruz Biotechnology, Heidelberg, Germany) was used. Immune complexes were visualized using a horseradish peroxidase-conjugated secondary antibody (Dianova, Hamburg, Germany and DAKO, Hamburg, Germany) in conjugation with a chemoluminescence detection system (Boehringer ± Mannheim, Mannheim, Germany) and exposure to Biomax MR ®lms (Eastman Kodak, Rochester NY, USA).
Primary hepatocyte culture and [
H]thymidine incorporation
Hepatocytes from FVB/NHSD and DkTbRII transgenic mice were isolated by a two-step perfusion technique (Braun et al., 1988) . Mice were anesthetized with Avertin and livers were perfused in situ with saline containing 7 mM potassium chloride and 10 mM HEPES pH 7.4 to remove hepatic blood. Livers were then perfused for 20 min with the same buer containing 0.5 mg/ml collagenase (Sigma, Deisenhofen, Germany) and 5 mM calcium chloride. Thereafter, livers were mechanically disrupted and cells were suspended and washed twice with Dulbecco's modi®ed Eagle's medium (DMEM; # 41965; Gibco ± BRL, Karlsruhe, Germany). Viability of cells was 495%. Contamination by non-parenchymal cells was less than 5%. Cells (2610 5 per dish) were plated on 35-mm dishes coated with collagen in DMEM containing 5% fetal bovine serum, 1 mM pyruvate, 0.2 mM aspartate, 1 mM proline, 0.2 mM serine, 2 mM glutamine, 0.5 mg of hydrocortisone and 1 mg of insulin per ml. After 3 h, fresh serumfree medium containing EGF (20 ng/ml) and various concentrations of TGF-b 1 (R&D Systems, Wiesbaden, Germany) were added. The medium was replaced every 24 h. DNA synthesis in primary hepatocytes was measured after incubation of the cells with [ To compare the level of DkTbRII expression of transgenic mice in vivo (line 11, male) with primary hepatocytes of transgenic mice in vitro (line 11, male) we isolated primary hepatocytes from transgenic mice and split them into two fractions. RNA was extracted from half of the transgenic hepatocytes shortly after isolation of hepatocytes. The other half was kept for 72 h under the above descibed culture conditions. After 72 h RNA was extracted. The level of expression of the dominant negative receptor from uninduced transgenic mice and hepatocytes from transgenic mice was then compared by Northern blot analysis. In addition, we extracted total RNA from liver of transgenic mice (line 11, male) after 64 weeks of DEN/PB treatment in order to compare DkTbRII mRNA expression under DEN/PB treatment with basal expression of uninduced transgenic mice (line 11, male).
Chemical hepatocarcinogenesis and histopathology
Transgenic mice as well as wild type mice were treated according to a hepatocarcinogenesis protocol consisting of tumor-initiation with DEN and tumor promotion with PB Pitot et al., 1987) . DEN (Sigma) was dissolved in PBS and given twice ip. at a dose of 5 mg/g bodyweight at age of 8 and 12 weeks. Initiation was followed by PB treatment (Sigma) in a concentration of 0.05% in food pellets. Eight mice of each group, four female and four male mice, were sacri®ced at each of the indicated time points after the beginning of the treatment with PB (8, 16, 24, 32, 40, 48 and 56 weeks) and were further analysed. Liver and bodyweight were determined at each time point. At week 64 all remaining mice were killed, since the incidence of hepatocellular carcinoma increased and a high percentage of transgenic mice started to suer from cachexia or tumor burden. In total between 80 to 90 mice of each transgenic line and an equal number of wild type mice entered the study.
All mice in the carcinogenesis protocol were subjected to a complete necropsy and tissues were immediately ®xed in 4% neutral-buered formaldehyde, embedded in paran, sectioned at 2 mm and stained with hematoxylin/eosin by standard methods. For detection of pathologic liver morphology at least eight representative sections of each liver were made and evaluated by a senior hepatopathologist in a blinded fashion (PS). Liver pathology was scored into preneoplastic lesions (basophilic, eosinophilic, tigroid cell, clear cell and mixed foci) and hepatocellular carcinomas. In addition, we sacri®ed 60 untreated transgenic mice at the age of 18 ± 24 months. A complete autopsy with inspection of the liver, lung, kidneys, intestine, spleen and heart for macroscopically visible tumors was performed. Suspicious tissue lesions were examined histopathologically.
Immunohistology was performed on 5 mm cryosections. After preblocking with 1% BSA, 5% FCS, 0.5% Tween 20, 0.1 M MgCl 2 in 10 mM Tris-HCl (pH 7.4) tissues were incubated with an antibody speci®c for the type II TGF-b receptor (H-567, 1 : 10; Santa Cruz Biotechnology, USA) overnight at 48C. The secondary antibody was conjugated to alkaline phosphatase and used in a 1 : 1500 dilution (Boehringer Mannheim, Cat. No 1214 632). As a control reaction normal rabbit serum was used at a concentration matching the immunoglobulin content of the speci®c primary antibody. The secondary antibody was incubated at 378C for 60 min. Endogeneous phosphatase activity was quenched by addition of 1 mM levamisol in the substrate solution. To increase the expression of DkTbRII in transgenic mice acute phase response was induced by intraperitoneal injection of 50 mg lipopolysaccharide (LPS; L-8274; Sigma Chemicals, Heidelberg, Germany). Animals were sacri®ced 15 h after induction with LPS since transgene expression under the control of the CRP gene is highest at this time point (Ciliberto et al., 1987) . Uninduced and LPS-induced transgenic and wild type mice were examined.
Statistics
The data are presented as mean+s.d. For statistical comparison of TGF-b 1 induced inhibition of [ 3 H]thymidine incorporation in hepatocytes the students t-test was used. The Fisher's exact test was applied to compare the frequency of premalignant and malignant tissue lesions in transgenic and wild type animals.
Abbreviations
The abbreviations used are: TGF-b, transforming growth factor-b; TbRII, transforming growth factor-b type II receptor; DkTbRII, dominant negative mutant of the TGFb type II receptor; CRP, C-reactive protein; HCC, hepatocellular carcinoma; PBS, phosphate-buered saline; DEN, diethylnitrosamine; PB, phenobarbital
